NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
Clinical Trials
7 trialsNCT04316169 2022-12-23
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
Medical College of Wisconsin
Phase 1 Withdrawn
NCT03238703 2018-12-27
Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer
Fred Hutchinson Cancer Center
Phase 4 Withdrawn
NCT02140437 2015-12-29
Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC
Fudan University
Phase 2 Withdrawn
NCT01814865 2013-12-20
Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer
British Columbia Cancer Agency
Phase 2 Withdrawn
NCT00217659 2013-01-03
S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer
SWOG Cancer Research Network
Phase 2 Withdrawn
NCT00935558 2012-05-31
Dendritic Cell Based Therapy for Breast Cancer Patients
Herlev Hospital
Phase 2 Withdrawn